WFH 2012

 
 
 

The World Federation of Hemophilia 2012 World Congress took place July 8-12 in Paris, France.

 

Factor elicits promising results in hemophilia A mice

HT Staff Read Article
Published: 07/17/12

lab_mouse_240.jpg
Lab mouse

Preclinical research suggests a recombinant factor VIII Fc-fusion protein (rFVIIIFc) may have lower immunogenicity than rFVIII products currently on the market. Investigators compared rFVIIIFc to full-length rFVIII (Advate) and B-domain-deleted rFVIII (Xyntha) in mice with hemophilia A. The team presented their results at the World Federation of Hemophilia 2012 World Congress, which took place July 8-12 in Paris. The research was funded by Biogen Idec, the makers of rFVIIIFc. [Read Article]

Secondary prophylaxis reduces bleeding in hemophilia

HT Staff Read Article
Published: 07/13/12

bleeding_wound_240.jpg
Bleeding finger

Results of a phase 3 study indicate that the recombinant antihemophilic factor octocog alfa is effective as secondary bleeding prophylaxis in patients with severe hemophilia A. The product appeared to be well-tolerated, and it reduced bleeding frequency as secondary prophylaxis (ie, treatment after multiple bleeding episodes have occurred), when compared to on-demand treatment. These results were presented at the World Federation of Hemophilia 2012 World Congress. [Read Article]

Hemophilia patients plagued by professional challenges

HT Staff Read Article
Published: 07/11/12

Results of a large study suggest that 8 in 10 hemophilia patients feel their disorder has had a negative impact on their career. In fact, 1 in 5 patients said they have lost a job because of their condition. However, only 8% said they were unable to find employment because of it. These findings were presented at the World Federation of Hemophilia 2012 World Congress. The data are part of the HERO study, which evaluated the psychosocial aspects of living with hemophilia. [Read Article]

Innovations will prompt changes in standard of care, WFH prez says

HT Staff Read Article
Published: 07/10/12

Skinner_Mark_W_Credit_World_Federation_of_Hemophilia_230.jpg
Mark W. Skinner, JD
Photo courtesy of WFH

A “revolution” in hemophilia treatment is on the horizon and will require clinicians to rethink current practices, according to the president of the World Federation of Hemophilia (WFH). WFH President Mark W. Skinner, JD, presented this viewpoint at the opening session of the WFH 2012 World Congress, taking place July 8-12. Skinner said breakthroughs in hemophilia treatment are set to occur on all fronts over the next few years, ranging from biosimiliars to longer-lasting products to the real prospect of a . . .  [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}